Ceterix Orthopaedics is a technology company.
Ceterix Orthopaedics has raised $18.0M across 1 funding round.
Ceterix Orthopaedics has raised $18.0M in total across 1 funding round.
Ceterix Orthopaedics was a medical technology company that developed innovative surgical tools for arthroscopic procedures, particularly focused on meniscal preservation in knees.[1][2][4] Its flagship product, the NovoStitch Pro Meniscal Repair System, enabled surgeons to repair complex meniscal tears—such as horizontal, radial, bucket handle, root, and vertical tears—that were previously untreated or required meniscus removal (meniscectomy), a procedure linked to higher risks of arthritis or knee replacement.[2][3][5] The company served orthopedic surgeons treating soft tissue injuries in knees, hips, and shoulders, addressing the problem that only 15-20% of over 1.2 million annual U.S. meniscal tears receive repair rather than removal.[3] Ceterix demonstrated growth through venture funding from investors like Versant Ventures and an acquisition by Smith & Nephew in 2019 for $50 million upfront plus up to $55 million in performance-based payments, integrating its technology into a leading sports medicine portfolio.[3]
Ceterix Orthopaedics was founded in October 2010 in Menlo Park, California (with later operations in Fremont, CA), based on inventions by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine.[1][6] Dr. Saliman identified a key gap in arthroscopic surgery: the inability to place precise stitches in tight joint spaces while protecting nerves, arteries, and cartilage, limiting repairs to patterns feasible only in open procedures.[1] The company emerged from the ExploraMed incubator, with key figures like Josh (likely Josh Makower, given his role in founding multiple medtech firms via ExploraMed, including successful exits like Acclarent) and CEO Kevin (with prior leadership at DePuy and St. Francis Medical Technologies, overseeing billions in orthopedic revenue).[1] Early traction built on this clinical insight, leading to tools like NovoStitch Pro for meniscal repairs previously underserved.[3]
Ceterix rode the wave of minimally invasive orthopedics and sports medicine innovation, targeting the growing demand for joint preservation amid rising arthritis burdens from an aging population and active lifestyles.[2][3] Timing was ideal in the 2010s medtech boom, with arthroscopic procedures surging but repair rates lagging due to technical limitations—over 1.2 million U.S. meniscal surgeries yearly highlighted the unmet need.[3] Market forces like value-based care favoring durable repairs over removals, plus consolidation by giants like Smith & Nephew, favored Ceterix; its acquisition amplified influence by embedding NovoStitch into a $4.8 billion portfolio with global reach in orthopedics and sports medicine.[3] This advanced the ecosystem by setting benchmarks for complex tear repairs, encouraging further R&D in soft tissue technologies.[5]
Post-2019 acquisition, Ceterix's technology endures within Smith & Nephew, likely driving expanded adoption of meniscal repairs via combined systems like NovoStitch Pro and FAST-FIX 360.[3] Next steps involve scaling globally, leveraging sports medicine growth and AI-enhanced imaging for even precise interventions. Trends like personalized orthopedics and biologics integration could evolve its legacy, potentially doubling repair rates as projected and influencing knee health outcomes worldwide—cementing Ceterix's role from startup innovator to cornerstone of preserved mobility.[3]
Ceterix Orthopaedics has raised $18.0M in total across 1 funding round.
Ceterix Orthopaedics's investors include Aberdare Ventures, Johnson & Johnson Innovation, New Enterprise Associates (NEA), Pivotal bioVenture Partners, Versant Ventures.
Ceterix Orthopaedics has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Series B in May 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2014 | $18.0M Series B | Aberdare Ventures, Johnson & Johnson Innovation, New Enterprise Associates (NEA), Pivotal bioVenture Partners, Versant Ventures |